Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cobra Biologics and Novolytics Develop Bacteriophages Against Infection

Published: Wednesday, June 12, 2013
Last Updated: Wednesday, June 12, 2013
Bookmark and Share
Companies have achieved a breakthrough in the development of two Staphylococcus aureus-based phage products for Phase I clinical trials.

An existing process was transferred to Cobra’s phage team and a scope of work undertaken to further develop the process to increase yields for the two Staphylococcus aureus-based phage products. The controlled, high yield process provides Novolytics with a clear path forward to producing suitable GMP material for human clinical trials.

The worldwide emergence of ‘superbugs’ such as MRSA has coincided with the virtual drying up of new antibiotic drug development. Novolytics aims to lead the way in utilising nature’s own natural antidote, bacteriophages. The company’s lead product, NOVO12, is a phage cocktail administered as a gel for topical treatment of MRSA infections.

Cobra is set to present its methodology, approach, and acquired expertise in phage manufacture at the Phages 2013 conference taking place in Oxford, UK, in September 2013.

‘It is very exciting to be engaged with such novel phage products and to be actively assisting pioneering companies like Novolytics to introduce ground-breaking anti-infectives,’ said Peter Coleman, CEO of Cobra Biologics. ‘The phage team has considerable experience in developing processes for such novel products and looks forward to working closely with Novolytics.’

Novolytics CEO John Hardcastle added: ‘Cobra is helping Novolytics to produce bacteriophage cocktails that remain therapeutically active when produced to GMP standard and on an industrial scale. This is a critical factor for successful exploitation of the exciting potential that phage therapy offers.’


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cobra Biologics, Alligator Bioscience Announce Partnership
Partnership aims to develop second cell line for manufacture of immuno-oncology antibody ADC-1015 following ADC-1013 success.
Friday, June 24, 2016
Cobra Biologics, CPI Announce Collaboration
Cobra Biologics and the Centre for Process Innovation are collaborating on a project which will focus on the development of an Industrial Manufacturing Platform for Adeno-Associated Virus (AAV) production to support gene therapy and regenerative medicine.
Thursday, February 25, 2016
Cobra Biologics Appointed by University of Sheffield
Manufacturing service will scale production of growth hormone developed using ‘ProFuse’ Technology.
Tuesday, November 24, 2015
Cobra Biologics, The University of Manchester Announce Collaboration
Agreement brings together academic and industrial expertise for the scaled manufacture of therapeutic proteins.
Friday, September 25, 2015
Cobra Biologics and The University of Manchester Announce Collaboration
Agreement brings together academic and industrial expertise for the scaled manufacture of therapeutic proteins.
Friday, September 25, 2015
Cobra Biologics Develop Special Cell Line for Alligator Bioscience
The cell line designed expresses monoclonal antibodies that have been vital for the success of a clinical trial ran by Alligator Biosciences.
Thursday, May 28, 2015
Cobra Biologics and Tecrea Awarded £112K Innovate UK Grant to Develop AAV Scalable Production Bioprocess
‘Technology Inspired Innovation’ award to evaluate robust, large scale viral vector production.
Thursday, April 02, 2015
Cobra Biologics & The University of Manchester Receive £217K Innovate UK/BBSRC Funding
Awarded as part of £20M competition bringing innovative biotechnology projects to market.
Monday, February 23, 2015
Cobra Biologics Appoints CSO
Company announces the appointment of Dr Daniel C. Smith as its Chief Scientific Officer.
Wednesday, May 07, 2014
Cobra Biologics Granted Approval for Research Tax Credit
Company has recognized as an approved service provider for the period 2013 to 2015.
Wednesday, April 02, 2014
Cobra Biologics and BioCancell Announce Agreement
Agreement to manufacture promising cancer therapy drug.
Tuesday, March 04, 2014
Cobra Biologics, BioCancell Agreement for Promising Cancer Therapy Drug
The Companies have announced the agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials.
Monday, March 03, 2014
GMP Certification Boost for Cobra Biologics
Extended certification to include QC testing of registered products.
Wednesday, February 12, 2014
Cobra Biologics and Recopharma Enter Agreement
Agreement to utilize Cobra’s cell line development service- MaxXpress.
Wednesday, May 29, 2013
Cobra Biologics and Vaccibody Sign Agreement to Manufacture DNA Vaccine
Companies announce agreement to manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies.
Tuesday, May 14, 2013
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Unique Visual Stimulation May Be New Treatment for Alzheimer’s
Noninvasive technique reduces beta amyloid plaques in mouse models of Alzheimer’s disease.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!